News Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Market Closed - Nasdaq Other stock markets 03:59:47 2024-06-04 pm EDT			5-day change	1st Jan Change
31.43 ^USD	+0.06%		+4.73%	+136.32%

May. 23	Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing	MT
May. 22	Dyne Therapeutics Prices $325.5 Million Common Stock Offering	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dyne Therapeutics : Company Overview May 2024	May. 31	PU
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference	May. 30	GL
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares	May. 28	GL
Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing	May. 23	MT
Dyne Therapeutics Prices $325.5 Million Common Stock Offering	May. 22	MT
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock	May. 21	GL
Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept	May. 21	MT
Dyne Therapeutics Launches $300 Million Share Offering	May. 20	MT
Dyne Therapeutics Announces Proposed Public Offering of Common Stock	May. 20	GL
Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles	May. 20	MT
HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating	May. 20	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	May. 20	MT
Transcript : Dyne Therapeutics, Inc. - Special Call	May. 20
Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles	May. 20	MT
Dyne Therapeutics : ACHIEVE & DELIVER Clinical Update Presentation	May. 20	PU
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints	May. 20	GL
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints	May. 20	CI
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET	May. 19	AQ
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET	May. 19	GL
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Summary

Filters